Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer

Summary

Selpercatinib data in early-stage RET fusion-positive non-small-cell lung cancer was published in the New England Journal of Medicine. The article presents clinical trial results but lacks specific efficacy, safety, or outcome details in the provided excerpt.